Home
Trojantec is a biopharmaceutical Company focused on identifying, in-licensing and developing innovative oncology therapeutics. Trojantec is one of a few Companies in the World developing drugs that not only attack Cancer Cells, but more importantly, destroy Cancer Stem Cells. Through research and development in this novel, exciting field, we wish to achieve the next order of magnitude of efficacy against cancer.
Latest News
|
AACR Annual Meeting, April 6-10, 2013, Walter E. Convention Center, Washington, DC, USA Trojantec presented today, Sunday, April 7, 2013 at the Session: Tumor Biology ,Session Title: Cancer Stem Cell Targeting Therapies, its work on Cancer Stem Cells Therapeutics particularly, its lead product TR4, a Notch inhibitor. Read more... |
|
RECOMBINANT PROTEIN THERAPEUTICS, CHI's 12th Annual PepTalk, January 21, 2013, Palm Springs Convention Center, Palm Springs, California, USA Trojantec presented today(21st January 2013) at the RECOMBINANT PROTEIN THERAPEUTICS conference held in Palm springs, California its work on Cancer Stem Cells Therapeutics particularly, its lead product TR4, a Notch inhibitor. Read more... |
|
ESMO 2012, Vienna, Austria: Friday 28 September - Tuesday 2 October. Trojantec has announced that the Company's presentation entitled 'The Development of Cancer Stem Cells Therapeutics' has been published in the proceedings of ESMO 2012, held in Vienna, Austria from the 28th of September to the 2nd of October 2012. Read more... |
|
New treatments against cancer and cancer stem cells Trojantec has announced that the Company's work with TR1, prepared as a full manuscript entitled 'Generation of a selectively cytotoxic fusion protein against p53 mutated cancers', has been published on August 1, 2012 in the prestigious and widely read online journal called BioMed Central, a Science, Technology and Medicine publisher. Read more... |